Arcus Biosciences/$RCUS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arcus Biosciences
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
- Ticker
- $RCUS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 601
- Headquarters
- Hayward, United States
- Website
- arcusbio.com
RCUS Metrics
BasicAdvanced
$2.6B
-
-$3.86
0.81
-
Price and volume
Market cap
$2.6B
Beta
0.81
52-week high
$31.74
52-week low
$17.43
Average daily volume
2.2M
Financial strength
Current ratio
3.818
Quick ratio
3.753
Long term debt to equity
0.485
Total debt to equity
0.513
Interest coverage (TTM)
-44.18%
Profitability
EBITDA (TTM)
-476
Gross margin (TTM)
-324.79%
Net profit margin (TTM)
-393.16%
Operating margin (TTM)
-415.38%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-30.39%
Return on equity (TTM)
-90.82%
Valuation
Price to revenue (TTM)
18.17
Price to book
4.89
Price to tangible book (TTM)
4.89
Price to free cash flow (TTM)
-4.476
Free cash flow yield (TTM)
-22.34%
Free cash flow per share (TTM)
-3.988
Growth
Revenue change (TTM)
-55.34%
Earnings per share change (TTM)
25.71%
3-year revenue growth (CAGR)
-1.11%
3-year earnings per share growth (CAGR)
-0.68%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
Analyst projections of the future price of Arcus Biosciences stock.
Bulls say / Bears say
In first-line kidney cancer, casdatifan plus zimberelimab produced a 50% confirmed response rate and 69% progression-free survival at 12 months in 30 patients. That early activity could support a differentiated treatment option if it holds up in larger trials. (Arcus Biosciences)
For second-line kidney cancer, casdatifan plus cabozantinib achieved median progression-free survival of 14.5 months and 77% overall survival at 18 months in a 43-patient cohort. The encouraging signal is being tested in the Phase 3 PEAK-1 trial. (Arcus Biosciences)
In heavily pre-treated patients, pooled casdatifan monotherapy cohorts showed median overall survival of 35 months and a 36% response rate. These results suggest potential beyond earlier treatment lines and underpin plans for further registrational testing. (Arcus Biosciences)
Arcus has lost momentum in its TIGIT cancer programme: Phase 3 trials STAR-121 and STAR-221 were discontinued, and the company and AstraZeneca also ended PACIFIC-8. Gilead’s decision to let broader option rights lapse and give up its board seats highlights a weaker partner backdrop. (Arcus Biosciences)
Arcus remains loss-making and has no approved products generating sales; it reported a $91 million net loss in the second quarter and held $775 million in cash and investments at June-end. Management expects funding to last until at least the second half of 2028, but continued development spending could still make further capital raising necessary. (U.S. Securities and Exchange Commission)
Casdatifan’s positive signals come from relatively small, early-stage cohorts, with comparisons against benchmarks rather than direct randomised trials. The pivotal PEAK studies are still under way, so the apparent benefit may not be confirmed in larger controlled trials. (Arcus Biosciences, U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
Upcoming events
No upcoming events
RCUS News
AllArticlesVideos
Funds containing RCUS
Fund name | Fund size | $RCUS weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.15% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.15% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.15% |
iShares Ageing Population$AGED | $953M | 0.14% |
iShares Ageing Population£AGES | $953M | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.